Ekaterina A. Viktorova

Ekaterina A. Viktorova

Auto-generated profile, based on publicly available information

Ekaterina A. Viktorova

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2021 in Russian Journal of Allergy
Verified
Journal Article
Open access
PDF file
EBElena Bliznetz
Elena Bliznetz
EVEkaterina A. Viktorova
Ekaterina A. Viktorova
EVElena A. Vishneva
Elena A. Vishneva
EDEliso M. Dzhobava
Eliso M. Dzhobava
NINatalya I. Il'INa
Natalya I. Il'INa
ЩЮЩербина Анна Юрьевна
Щербина Анна Юрьевна
Hereditary angioedema is a rare, potentially life-threatening genetic disease that manifests with skin and mucous/submucosal swelling that occurs under the influence of bradykinin. The clinical guidelines for hereditary angioedema (code for the International Statistical Classification of Diseases and Related Health Problems D84.1) were developed in December 2020 by the Russian Association of Allergology and Clinical Immunology, Association of Medical Geneticists, National Association of Experts in the Field of Primary Immunodeficiencies, Union of Pediatricians of Russia. In December 2020, the project was approved at a meeting of the Scientific and Practical Council of the Ministry of Health of the Russian Federation (December 10, 2020 No. 743/12). The clinical guidelines are devoted to optimizing the clinical care of patients with hereditary angioedema. The topic is relevant owing to the under-diagnosis of hereditary angioedema and insufficient awareness of doctors of various specialties about this problem, as well as the difficulties in managing this category of patients. The clinical guidelines contain information about the epidemiology, etiology, classification, pathogenesis, and common clinical manifestations of hereditary angioedema. Thus, the paper described actual diagnostic approaches and differential diagnosis of hereditary angioedema and established its diagnostic criteria. Medical care algorithms to patients with hereditary angioedema at the prehospital and hospital stages are also described. The principles of pharmacotherapy, including long-term prophylaxis, short-term prophylaxis, and acute therapy, for hereditary angioedema are also presented. Treatment regimens are stratified according to patients age and gender. Non-drug measures for the prevention hereditary angioedema attacks are considered. Sections were also added in the edition of the new clinical guidelines of hereditary angioedema. Clinical guidelines for hereditary angioedema are intended for practicing doctors of all specialties, students and teachers of medical universities, residents, graduate students of medical universities.

29 June 2019 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
ATA. I. Terentieva
A. I. Terentieva
EVE. A. Viktorova
E. A. Viktorova
VZV. V. Zaharova
V. V. Zaharova
DKD. V. Konovalov
D. V. Konovalov
VBV. I. Burlakov
V. I. Burlakov
AKA. L. Kozlova
A. L. Kozlova
This article describes clinical case of a child with proteasome-associated autoinflammatory syndrome-2 (PRAAS2). First two cases in unrelated boys were described in July, 2018 by M. Cecilia Poli, Frederic Ebstein. We describe another case of PRAAS2. Mutations of the POMP-gene underlie PRAAS2 pathogenesis, causing defects of the POMP protein which plays important role in proteasomes maturation and leads to the clinical symptoms observed in three described cases. We also provide a short PRAAS2 background description, as well as key pathogenesis components, clinical findings description and analysis of three known PRAAS2 cases. Parents gave their consent to use personal data, including photos for clinical research and publications.

14 December 2020 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
NKN.Yu. Kan
N.Yu. Kan
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
YRYulia Rodina
Yulia Rodina
NKN.B. Kuzmenko
N.B. Kuzmenko
EDE.A. Deordieva
E.A. Deordieva
RHRostov-On-Don Rostov Regional Children'S Clinical Hospital
Rostov-On-Don Rostov Regional Children'S Clinical Hospital
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.

9 February 2018 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
OSO. A. Shvetz
O. A. Shvetz
EDE. V. Deripapa
E. V. Deripapa
IAI. N. Abramova
I. N. Abramova
EVE. A. Victorova
E. A. Victorova
YRYu. A. Rodina
Yu. A. Rodina
ASA. Yu. Shcherbina
A. Yu. Shcherbina
Autoimmune lymphoproliferative syndrome is a primary immunodeficiency caused by defects in proteins participating in theFas-mediated apoptosis pathway, manifesting with benign and malignant lymphoproliferation and immune cytopenias. Sirolimusis an inhibitor of mammalian target of rapamycin (mTOR-I), it regulates cell growth and proliferation. In this article, we describethe efficacy and safety of sirolimus treatment in a group of 22 patients with ALPS. We demonstrate the effectiveness of therapy,both in the usual dose of 2–3 mg/m2, and in reduced dose of 1–2 mg/m2. Treatment with sirolimus not only leads to theresolution of the symptoms of lymphoproliferation and cytopenias, but also to the normalization of biomarkers, for example, thevitamin B12 level and double negative T-lymphocytes.

12 January 2019 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
AKA. K. Kantulaeva
A. K. Kantulaeva
NKN. B. Kuzmenko
N. B. Kuzmenko
EDE. V. Deripapa
E. V. Deripapa
DYD. V. Yukhacheva
D. V. Yukhacheva
EVE. A. Victorova
E. A. Victorova
ASA. Y. Shcherbina
A. Y. Shcherbina
The hyper-IgE syndrome with dominant-negative mutations in signal transducer and activator of transcription 3 (STAT3) gene is a combined primary immunodeficiency characterized by severe bacterial infections (skin and lungs with bullae formation), characteristic phenotype, serum IgE elevation, eosinophilia, as well as connective tissue, and bone anomalies. Patients also have high risk of cancer. STAT3 is a transcription factor important for the JAK/STAT signaling pathway, which plays the key role in the synthesis of cytokines, hormones, and bioactive agents. Hyper-IgE syndrome therapy includes antimicrobial prophylaxis, immunoglobulin replacement, and use of bisphosphonates. Hematopoietic stem cell transplantation is an alternative way for the disease treatment. Here we describe a patient with severe autosomal dominant hyper-IgE-syndrome with thte loss-of-function mutation in the STAT3 gene. Patient's parents agreed to use personal dats and photos in research and publications.

9 July 2023 in Russian Journal of Allergy
Verified
Journal Article
Closed access
PDF file
TLTatiana Latysheva
Tatiana Latysheva
IMIrina A. Manto
Irina A. Manto
LALiubov V. Aleshina
Liubov V. Aleshina
EBElena N. Bobrikova
Elena N. Bobrikova
EVEkaterina A. Viktorova
Ekaterina A. Viktorova
ЩЮЩербина Анна Юрьевна
Щербина Анна Юрьевна
BACKGROUND: Hereditary angioedema with C1 inhibitor deficiency is a rare disease caused by a deficiency and/or a decrease in the functional activity of the C1 inhibitor. The primary symptom of this condition is recurrent angioedema of various localizations. According to the modern concept of treatment, the therapy aims to stop emerging angioedema and prevent death as well as achieve complete control of the disease and a high quality of life. Lanadelumab is a modern medicine developed and used to prevent attacks in patients with hereditary angioedema aged 12 years. AIM: A retrospective study (IISR-2021-200085) was conducted to evaluate the efficiency and safety of lanadelumab in real-life practice in Russia. MATERIALS AND METHODS: In all, 16 patients with hereditary angioedema and C1 inhibitor deficiency were enrolled at the initiation of lanadelumab treatment. The patients were predominantly female (81%; 13/16). The average age of patients was 29.9 years; 19% (3/16) of the patients were adolescents. The effectiveness was evaluated by comparing the patient-reported attack rates. The following PROs for the adults only were assessed initially and during the treatment: angioedema activity score, angioedema control test (AECT), angioedema quality of life questionnaire (AE-QoL), and hereditary angioedema activity score. The incidences of adverse events were evaluated. RESULTS: Before lanadelumab, 69% (11/16) of the patients received alternative long-term prophylaxis, which was canceled after the start of lanadelumab treatment. The average number of attacks per month and treated attacks per month prelanadelumab were 10 and 4.7 per patient, respectively. After 6 months of treatment, these values were 0.26 and 0.09, respectively (10 patients were symptom free at 6 months after the initiation of the treatment). After 3 months of treatment, the mean AECT values improved from 5.6 to 14.2 (p 0.001), and all patients showed adequate disease control. After 6 months of treatment, AE-QoL decreased from 58 to 19 (p 0.001). No serious adverse events related to lanadelumab were observed. CONCLUSION: Our study demonstrated that the composite effect of lanadelumab minimizes the attack rate and improves the quality of life in patients with hereditary angioedema. A good safety profile of lanadelumab is shown.